Letters New oral anticoagulants and atrial fibrillation

Differentiating between “no proof of difference” and “proof of no difference” for new oral anticoagulants

BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1955 (Published 06 March 2014) Cite this as: BMJ 2014;348:g1955
  1. Andrea Messori, coordinator1,
  2. Valeria Fadda, researcher2,
  3. Roberta Gatto, thesis student2,
  4. Dario Maratea, researcher2,
  5. Sabrina Trippoli, researcher1
  1. 1HTA Unit, Area Vasta Centro Toscana, Regional Health System, 50100 Firenze, Italy
  2. 2Department of Pharmaceutical Sciences, Area Vasta Centro Toscana, Regional Health System, 50100 Firenze, Italy
  1. andrea.messori.it{at}gmail.com

In the past few years, network meta-analysis has increasingly been used in research on comparative effectiveness.1 Recently, 13 meta-analyses of new oral anticoagulants for the prevention of stroke and systemic embolism in patients with atrial fibrillation have been conducted and published over a short time.2 Although simultaneous publication of numerous meta-analyses on the same subject has disadvantages …

View Full Text

Sign in

Log in through your institution

Subscribe